Solventum raises 2026 guidance as Q2 sales rise 2.2% and adjusted EPS hits $2.55
Solventum reported second-quarter 2026 net sales of $2.2 billion, up 2.2% reported and 9.5% organic, with GAAP diluted EPS of $0.53 and adjusted diluted EPS of $2.55. The company raised its full-year 2026 guidance for organic sales growth, adjusted EPS and free cash flow, and announced its intent to separate the Health Information Systems segment. GAAP results were weaker in some areas, including a GAAP operating margin of 8.2% versus 9.9% a year earlier.
Key points
- Q2 net sales of $2.2 billion, up 2.2% reported and 9.5% organic; GAAP diluted EPS $0.53 vs. $0.51 a year earlier
- Adjusted diluted EPS of $2.55 vs. $1.69 in Q2 2025, a 50.9% increase
- 2026 adjusted EPS guidance raised to $7.10 to $7.20, from the upper end of the prior $6.40 to $6.60 range
- Intent to separate Health Information Systems segment; six-month net income was $105 million, down 53.7%
The filing
Written by AI on Nov 8, 2026, 1:11 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.